鶹ý

Fast-Acting Novel Depression Tx; Lumryz Label Expanded; GLP-1s for Addiction?

— News and commentary from the psychiatry world

MedpageToday
Illustration of a brain shaped maze.

As an adjunctive treatment to antidepressants, -- a novel, first-in-class intracellular modulator of mTORC1 that was developed to provide a rapid-onset response -- was safe and effective in adults with major depressive disorder in a phase IIa study, said Supernus Pharmaceuticals.

Risk of sudden cardiac death was 4.5-fold higher among compared with the general population, a Danish study found. (Heart)

The FDA expanded the for cataplexy or excessive daytime sleepiness to include children with narcolepsy ages 7 years and up, Avadel Pharmaceuticals announced.

Eight distinct forms of moderated developmental changes in psychiatric risk and cognitive ability in different ways, according to a cohort study of kids. (JAMA Psychiatry)

Experts share why mental illness may . (New York Times)

Adults with a history of on a GIP and/or GLP-1 receptor agonist for type 2 diabetes or obesity had significantly lower rates of opioid overdose and alcohol intoxication in a real-world analysis. (Addiction)

After the FDA rejected Lykos Therapeutics' MDMA-assisted post-traumatic stress disorder therapy in August, it is planning an additional phase III trial and a potential independent third-party review of prior phase III clinical data following a recent meeting with the agency.

A psychiatrist who helped write the 1973 "Goldwater rule" that kept many experts from commenting on said he would recommend dementia tests for Republican presidential nominee Donald Trump. (HuffPost)

A retrospective study suggested that maternal prenatal cannabis use around 8 to 10 weeks' gestation was not linked to . (JAMA Network Open)

More than 2,400 Kaiser Permanente in Southern California, citing increased workloads and staffing shortages. (AP)

People with major depressive disorder showed after 10 weeks of home-based transcranial direct current stimulation in a randomized phase II trial. (Nature Medicine)

A Lancet Psychiatry Commission was announced with the goal of offering evidence-based recommendations to limit the harms of .

The Federal Communications Commission voted to require that all calls to the be routed by geolocation. (Roll Call)

  • author['full_name']

    Kristen Monaco is a senior staff writer, focusing on endocrinology, psychiatry, and nephrology news. Based out of the New York City office, she’s worked at the company since 2015.